Which is a by-product of fat breakdown in the absence of insulin and accumulates in the blood and urine?

Glargine is a long-acting insulin analog formulated with a low pH of 4, which causes it to precipitate into micro-crystals upon subcutaneous injection. This allows for a slow, constant release into the systemic circulation, providing a stable basal concentration for approximately 24 hours. Mixing this acidic solution with other insulins shifts the pH, causing unpredictable precipitation and altering the pharmacokinetics of both medications.

A. Do not mix with other insulins: The acidic nature of glargine is essential for its unique extended-release mechanism. If it is mixed in the same syringe with a neutral pH insulin, like regular or NPH, the glargine may precipitate prematurely or become cloudy. This compromises the basal coverage and can lead to dangerous fluctuations in glycemic control.

B. Administer the total daily dosage in two doses: Glargine is specifically engineered to provide a 24-hour duration of action with a single daily injection. While a small subset of patients may require split dosing for better coverage, the standard teaching is a once-daily administration. This promotes patient adherence and mimics the natural basal secretion of the pancreas.

C. It is rapidly absorbed and has a fast onset of action: Unlike bolus insulins, glargine has an onset of approximately 1 to 2 hours and lacks a clinical peak. It is categorized as long-acting and is never used for acute prandial correction of blood glucose levels. Rapidly absorbed insulins, such as lispro or aspart, are used for mealtime coverage.

D. Draw up the drug first, then add regular insulin: Since glargine cannot be mixed with any other insulin, the sequence of drawing up medications in a single syringe is irrelevant. Each medication must be administered in a separate syringe at different anatomical sites. Attempting to combine them in one syringe will destroy the molecular stability of the glargine.

Oral antidiabetic agents, such as sulfonylureas or meglitinides, lower blood glucose by stimulating pancreatic secretion or improving insulin sensitivity. The most critical adverse effect is a rapid decline in plasma glucose levels below 70 mg/dL. Severe episodes can lead to neuroglycopenia, manifested by confusion, seizures, or loss of consciousness if not promptly treated.

A. Polyuria: Excessive urination is a hallmark of hyperglycemia, where osmotic diuresis occurs as the kidneys excrete excess glucose. While common in undiagnosed or poorly managed diabetes, it is not a direct side effect of glucose-lowering medications. Monitoring for this symptom helps identify therapeutic failure rather than acute drug-induced complications.

B. Blurred vision: Visual disturbances often occur due to osmotic shifts in the lens during periods of fluctuating or very high blood sugar. This symptom is generally associated with the initial presentation of diabetes or chronic lack of glycemic control. It is less likely to be a primary indicator of an acute adverse reaction to oral medications.

C. Polydipsia: Excessive thirst is the body’s compensatory mechanism to counter the fluid loss caused by osmotic diuresis in hyperglycemic states. Like polyuria, it indicates that the oral agent may not be sufficiently controlling the client's blood glucose levels. It serves as a clinical marker for the need to increase or adjust the medication dosage.

D. Hypoglycemia: Pharmacological stimulation of insulin release can cause blood sugar to drop to dangerously low levels, especially if meals are skipped. The nurse must monitor for autonomic symptoms like diaphoresis, tachycardia, and tremors. This represents the most immediate and life-threatening risk associated with specific classes of oral antidiabetic therapy.